ArticleOncotarget2016

[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.

Laurence Booth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.